Cronos Group Stock Forecast
NASDAQ: CRONHealth Care Medicinal Chemicals and Botanical Products USD
Market open · Delayed 15 min · as of Oct 8, 10:58 AM ET
CRON analyst consensus
Consensus (4 analysts)
strong_buy
Avg. price target
$2.46-22.64%
- Strong buy 0
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Cronos Group (2026-10-08), 3 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $2.46, with a high estimate of $2.46 and a low estimate of $2.46. The average target implies downside of 22.6% from the current price of $3.18.
The spread between the highest and lowest targets is 0.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CRON.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 75% |
| Hold | 1 | 25% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $2.46 | -22.64% |
| Average target | $2.46 | -22.64% |
| High target | $2.46 | -22.64% |